China Pharma Glossary: Regulatory, NRDL, VBP & 18A Terms
Plain-English reference guide to China’s pharmaceutical institutions and rules: NMPA, CDE, Class 1 drugs, NRDL, VBP, Dual-Channel pharmacies, DRG/DIP, and HKEX 18A.
Overseas executives, investors, and reporters tracking China’s biopharma market routinely encounter regulatory classifications, procurement mechanisms, and exchange rules whose English translations do not explain how they work in practice. This reference page defines the core terms used across China Pharma Desk coverage and links to recent examples.
1. Regulatory Agencies & Drug Registration
- NMPA (National Medical Products Administration): China’s national drug and medical-device regulator, responsible for marketing authorizations, post-market pharmacovigilance, and GMP inspections.
- CMDE (Center for Medical Device Evaluation): NMPA's national technical evaluator for medical devices, including IVDs. Under NMPA Notice No. 40 of 2026, eligible Class III devices with finalized design and necessary nonclinical studies completed can seek clinical-protocol consultation from January 1, 2027. Applicants outside the innovative-device procedure use a provincial route if domestic, or a China-based agent if overseas.
- CDE (Center for Drug Evaluation): The technical review arm under NMPA that evaluates IND/CTA filings, NDAs/BLAs, bioequivalence filings, and technical guidelines.
- Class 1 Innovative Drugs (Category 1): A registration category used for innovative medicines within China's drug-specific classification systems. Check the actual approval category and catalogue entry when applying class-specific access policies; the category is not a substitute for evidence of clinical benefit. See our analysis of Class 1 and broader hospital-access rules.
- Class 2 Modified New Drugs: Products with new dosage forms, routes, salts, or new indications based on known active ingredients demonstrating clinical advantages.
- BE Filing vs. Clinical Trial Application (IND/CTA): Eligible bioequivalence studies conducted in China use a 15-working-day administrative filing on CDE’s platform rather than a full 60-working-day IND review, whereas clinical-endpoint BE studies or patient pharmacodynamic studies still require a CTA (see our analysis of CDE’s revised BE filing procedure).
- GQCE (Generic Quality and Efficacy Consistency Evaluation): China’s mandatory bioequivalence and pharmaceutical-equivalence qualification required for generic drugs to compete in national volume-based procurement alongside originator brands.
- MAH (Marketing Authorization Holder): The legal entity holding a Chinese drug registration certificate and bearing full lifecycle responsibility for quality, manufacturing, and pharmacovigilance, even when production is outsourced to a CMO.
- HGR (Human Genetic Resources): Regulatory oversight governing collection, preservation, and cross-border sharing or transfer of Chinese clinical biospecimens and genetic data in multi-regional clinical trials (MRCTs) and outbound partnerships.
2. Market Access, Pricing & Hospital Channels
- NHSA (National Healthcare Security Administration): The cabinet-level agency administering China’s basic medical insurance funds, NRDL price negotiations, DRG/DIP hospital payment reforms, and national volume-based procurement.
- NRDL (National Reimbursement Drug List): China’s nationwide public medical-insurance catalogue, updated annually through structured pharmacoeconomic review and price-cut negotiations for innovative drugs. NRDL inclusion unlocks public reimbursement but does not automatically guarantee hospital stocking (see our TGCT commercial-access analysis).
- Commercial Health Insurance Innovative Drug List: A parallel catalogue recommended for commercial-insurance benefit design. Basic medical-insurance pooling and work-injury insurance funds do not pay for these listed drugs; actual commercial-policy coverage depends on the policy. Hospital-access and specified monitoring support are separate from the funding source. Under NHSA Notice No. 29 of 2026, relevant support continues for two agreement periods (four years) after a medicine transfers to basic insurance. See the relma-cel transfer and 2026 catalogue analysis.
- VBP (Volume-Based Procurement): National, inter-provincial alliance, or provincial tenders trading steep price reductions for guaranteed public-hospital purchasing allocations. Execution dates for procurement-platform listing, retail price resets, and insurance payment standards are set province by province (see our Fujian and Beijing 12th VBP calendar breakdown).
- Insurance Payment Standard: The benchmark price up to which public medical insurance calculates reimbursement for a drug group; it is a calculation base subject to deductibles and co-pay ratios, not a flat guaranteed payout.
- Hospital P&T Committee & “One Generic, Two Specs”: Hospital formulary review assesses clinical need and capacity to use a medicine. The four-agency Notice No. 18 of 2026 gives specified support to Class 1 drugs in either insurance catalogue, while NHSA Notice No. 29 separately permits specification-limit relief for negotiated medicines. A ban on local-authority total variety/specification caps is distinct from hospital clinical review. Performance-monitoring exclusions and DRG/DIP payment adjustments also have separate conditions. See the provision-by-provision analysis.
- Dual-Channel (Shuangtongdao) Pharmacies: Designated retail specialty pharmacies where patients can fill prescriptions for negotiated NRDL innovative drugs with the same public insurance reimbursement as hospital outpatient dispensaries when a hospital has not yet stocked the product.
- DRG / DIP Payment: Diagnosis-Related Group and Diagnosis-Intervention Packet prospective hospital payment systems under NHSA, which create inpatient cost-control incentives unless innovative drugs qualify for case-by-case exclusion or separate payment.
3. Capital Markets & Corporate Filings
- HKEX Chapter 18A (“-B” Stocks): Hong Kong Stock Exchange rules allowing pre-revenue biotech companies to list with a
-Bstock-name suffix once core products advance past Phase 1 under recognized regulators, making HKEX filings a primary English-language source for Chinese deal terms and cash runways. - SSE STAR Market Fifth Listing Standard: Shanghai’s science-and-technology board pathway for pre-profit biopharma companies with core pipelines in late clinical development and validated institutional backing.
- CNInfo (cninfo.com.cn): The CSRC-designated statutory disclosure repository for Shanghai, Shenzhen, and Beijing Stock Exchange issuers.
- NewCo Out-Licensing Structure: Cross-border transactions in which a Chinese biotech licenses ex-China (or global) rights for an early- or mid-stage molecule into a newly formed overseas entity backed by international venture funds in exchange for upfront cash, equity stakes, and milestones.
4. Clinical Registries & Labeling Nuances
- China Drug Trial Registry (CTR Number): CDE’s mandatory registry (
chinadrugtrials.org.cn) for registration-directed clinical trials and BE studies in China, identified byCTR202Xxxxxnumbers; investigator-initiated studies often register onChiCTR, and global or outbound programs frequently dual-register onClinicalTrials.gov(NCTnumbers). - Population & Guideline Cutoffs: Chinese clinical guidelines and NMPA labels can diverge from U.S. FDA or EMA thresholds—such as overweight/obesity BMI cutoffs of 24/28 kg/m² under Chinese guidelines versus 27/30 kg/m² in Western trials (see our brief on Lilly’s oral GLP-1 China label).
Clarified November 14, 2026: Separated the scopes of hospital-access provisions and removed a registration-category example that could be read across different drug types.